Unknown

Dataset Information

0

Enhancing an Oxidative "Trojan Horse" Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside.


ABSTRACT: The turn-on mutations of the KRAS gene, coding a small GTPase coupling growth factor signaling, are contributing to nearly 25% of all human cancers, leading to highly malignant tumors with poor outcomes. Targeting of oncogenic KRAS remains a most challenging task in oncology. Recently, the specific G12C mutant KRAS inhibitors have been developed but with a limited clinical outcome because they acquire drug resistance. Alternatively, exploiting a metabolic breach of KRAS-mutant cancer cells related to a glucose-dependent sensitivity to oxidative stress is becoming a promising indirect cancer targeting approach. Here, we discuss the use of a vitamin C (VC) acting in high dose as an oxidative "Trojan horse" agent for KRAS-mutant cancer cells that can be potentiated with another oxidizing drug arsenic trioxide (ATO) to obtain a potent and selective cytotoxic impact. Moreover, we outline the advantages of VC's non-natural enantiomer, D-VC, because of its distinctive pharmacokinetics and lower toxicity. Thus, the D-VC and ATO combination shows a promising path to treat KRAS-mutant cancers in clinical settings.

SUBMITTER: Burska AN 

PROVIDER: S-EPMC9657932 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Enhancing an Oxidative "Trojan Horse" Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside.

Burska Agata N AN   Ilyassova Bayansulu B   Dildabek Aruzhan A   Khamijan Medina M   Begimbetova Dinara D   Molnár Ferdinand F   Sarbassov Dos D DD  

Cells 20221101 21


The turn-on mutations of the <i>KRAS</i> gene, coding a small GTPase coupling growth factor signaling, are contributing to nearly 25% of all human cancers, leading to highly malignant tumors with poor outcomes. Targeting of oncogenic KRAS remains a most challenging task in oncology. Recently, the specific G12C mutant KRAS inhibitors have been developed but with a limited clinical outcome because they acquire drug resistance. Alternatively, exploiting a metabolic breach of KRAS-mutant cancer cell  ...[more]

Similar Datasets

| S-EPMC7418518 | biostudies-literature
| S-EPMC6010793 | biostudies-literature
| S-EPMC2845607 | biostudies-other
| S-EPMC8323819 | biostudies-literature
| S-EPMC4106035 | biostudies-literature
| S-EPMC10581169 | biostudies-literature
| S-EPMC6953083 | biostudies-literature
| S-EPMC2944701 | biostudies-literature
| S-EPMC8097374 | biostudies-literature
| S-EPMC5152938 | biostudies-literature